GlassScriptPhysician profile
Robert J Megna
NPI 1407872039
$40,392.22
in general payments reported to CMS, 2019-2025
39 companies · $624 in 2025
The $624 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $7,229 · 2021: $8,423 · 2022: $1,268 · 2023: $946 · 2024: $154 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,665 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.99 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28,169.92 | 2019-2025 | Repatha, Repatha |
| Corcept Therapeutics | $4,166.62 | 2019-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $2,257.98 | 2019-2025 | |
| Amarin Pharma, INC. | $882.77 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $737.14 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.57 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $426.21 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Heartflow, INC. | $425.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $417.71 | 2021-2023 | Verquvo, Belsomra |
| Astrazeneca Pharmaceuticals LP | $375.29 | 2019-2023 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $261.58 | 2019-2022 | |
| Dexcom, INC. | $208.43 | 2021-2024 | Dexcom G6 Transmitter |
| Mannkind Corporation | $164.92 | 2022-2024 | Afrezza |
| Lilly USA, LLC | $154.01 | 2019-2025 | Jardiance, Mounjaro, Baqsimi |
| Valeritas, INC. | $149.58 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Megna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.